Cases & Deals

  • Home
  • Practices
  • Infinity Pharmaceuticals develops global patent portfolio for IPI-549

Share

Infinity Pharmaceuticals develops global patent portfolio for IPI-549

January 2016

Client(s) Infinity Pharmaceuticals Inc.

Jones Day represents Infinity Pharmaceuticals, Inc. in the establishment of a global patent portfolio related to IPI-549, a small molecule selective inhibitor of phosphoinositide-3-kinase gamma (PI3K-gamma) for the treatment of cancer.

Contacts

Before sending, please note:

Information on www.jonesday.com is for general use and is not legal advice. The mailing of this email is not intended to create, and receipt of it does not constitute, an attorney-client relationship. Anything that you send to anyone at our Firm will not be confidential or privileged unless we have agreed to represent you. If you send this email, you confirm that you have read and understand this notice.